COMMUNIQUÉS West-GlobeNewswire

Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year NEW [...]
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene [...]
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The [...]
Apollomics Reports First Half 2025 Financial Results
22/12/2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025
Wegovy ® pill showed a mean weight loss of 16.6% in the OASIS 4 trial 1 Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse [...]
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and Evidence Gaps Explained New York, Dec. 22, 2025 ( [...]
Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded.
22/12/2025
Worcester, MA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar ® is proud to report; Following its first of its kind court victory on behalf of Vystar Corp. (“Vystar”) against EMA Financial, [...]
Alvotech’s Financial Calendar for 2026
22/12/2025
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the [...]
Celularity Announces Closing of Financing Transactions
22/12/2025
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the [...]
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
22/12/2025
Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“ [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/12/2025
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]
ALK – Financial calendar for the 2026 financial year
22/12/2025
2026 financial calendar for ALK ( ALKB:DC / OMX: ALK B ): 23 January 2026: Silent period 20 February 2026: Annual report 2025 16 March 2026 at 4.00 p.m.: Annual General Meeting Written requests to have specific business [...]
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
22/12/2025
- Halneuron ® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically [...]
PracticeLink Supports the Next Generation of Clinicians with Fall 2025 First Practice Fund Scholarships
22/12/2025
ST. LOUIS and HINTON, West Virginia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the leading online physician job board, announced today the [...]
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
22/12/2025
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-treated participants regained previously [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2025
22/12/2025
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040
22/12/2025
COMMUNIQUE DE PRESSE LE BREVET POUR LE MASITINIB DANS LE TRAITEMENT DE LA DRÉPANOCYOSE A ÉTÉ OFFICIELLEMENT ACCORDÉ AUX ÉTATS-UNIS AVEC UNE PROTECTION JUSQU'EN 2040 CETTE DÉCISION RENFORCE LE PORTEFEUILLE DE PROPRIÉTÉ [...]
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
22/12/2025
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY [...]

Pages